Passage Bio
PASG----
Passage Bio (PASG)
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Passage Bio Analyst Rating
View MoreForecast & Rating
Jun 26, 2026Price forecast
$15.50216.33%
Forecast & RatingBuy
3analysts
- Strong buy33.33%
- Buy0.00%
- Hold66.67%
- Sell0.00%
- Strong sell0.00%
News
- prnewswire · 11 hours ago
13:41 ET$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG
- TradingView · Jul 2 at 08:26 PM
Lynx1 Capital Management Discloses Investment at Passage BIO with 21.0% Stake
- PUBT · Jun 29 at 03:31 PM
Lynx1 Capital Management LP buys $206,064 of Passage Bio common shares
- benzinga_article · Jun 25 at 12:05 PM
12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga_article · Jun 25 at 07:05 AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga_article · Jun 24 at 04:05 PM
9 Health Care Stocks Moving In Wednesday's After-Market Session
